India, June 22 -- Apogee Therapeutics, Inc. (APGE) shares surged 46.72 percent, gaining $42.23 to $132.61 on Monday, after AbbVie announced a definitive agreement to acquire the biotechnology company in an all-cash transaction valued at approximately $10.9 billion.
The stock is currently trading at $132.61, compared with its previous close of $90.38 on the Nasdaq. During the session, shares opened at $132.55 and traded in a narrow range between $132.50 and $133.00. Trading volume reached 31.26 million shares, far exceeding the average daily volume of 974,516 shares.
Under the terms of the deal, AbbVie will acquire all outstanding Apogee shares for $135.11 per share in cash, representing a significant premium to the stock's prior closing p...